Exact Mass: 880.410582

Exact Mass Matches: 880.410582

Found 66 metabolites which its exact mass value is equals to given mass value 880.410582, within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error 0.01 dalton.

   

FT-0699926

3-[(1R,2S,3S,5Z,7S,8S,9Z,13S,14Z,17R,18R)-3,13,17-tris(2-carboxyethyl)-2,7,18-tris(carboxymethyl)-1,2,5,7,12,12,15,17-octamethyl-3,8,13,18,19,22-hexahydrocorrin-8-yl]propanoic acid

C45H60N4O14 (880.410582)


   

Precorrin 8

Precorrin 8X; Precorrin 8; Precorrin-8X

C45H60N4O14 (880.410582)


   

PGP(16:0/PGJ2)

[(2S)-3-({[(2R)-3-(hexadecanoyloxy)-2-{[(5Z)-7-[(1S,5R)-5-[(1E,3S)-3-hydroxyoct-1-en-1-yl]-4-oxocyclopent-2-en-1-yl]hept-5-enoyl]oxy}propoxy](hydroxy)phosphoryl}oxy)-2-hydroxypropoxy]phosphonic acid

C42H74O15P2 (880.4502714)


PGP(16:0/PGJ2) is an oxidized phosphoglycerophosphate (PGP). Oxidized phosphoglycerophosphates are glycerophospholipids in which a phosphoglycerol moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphoglycerophosphates belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphoglycerophosphates can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PGP(16:0/PGJ2), in particular, consists of one chain of one hexadecanoyl at the C-1 position and one chain of Prostaglandin J2 at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PGPs can be synthesized via three different routes. In one route, the oxidized PGP is synthetized de novo following the same mechanisms as for PGPs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PGP backbone, mainely through the action of LOX (PMID: 33329396).

   

PGP(PGJ2/16:0)

[(2S)-3-({[(2R)-2-(hexadecanoyloxy)-3-{[(5Z)-7-[(1S,5R)-5-[(1E,3S)-3-hydroxyoct-1-en-1-yl]-4-oxocyclopent-2-en-1-yl]hept-5-enoyl]oxy}propoxy](hydroxy)phosphoryl}oxy)-2-hydroxypropoxy]phosphonic acid

C42H74O15P2 (880.4502714)


PGP(PGJ2/16:0) is an oxidized phosphoglycerophosphate (PGP). Oxidized phosphoglycerophosphates are glycerophospholipids in which a phosphoglycerol moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphoglycerophosphates belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphoglycerophosphates can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PGP(PGJ2/16:0), in particular, consists of one chain of one Prostaglandin J2 at the C-1 position and one chain of hexadecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PGPs can be synthesized via three different routes. In one route, the oxidized PGP is synthetized de novo following the same mechanisms as for PGPs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PGP backbone, mainely through the action of LOX (PMID: 33329396).

   

PGP(16:1(9Z)/20:4(6Z,8E,10E,14Z)-2OH(5S,12R))

[(2S)-3-({[(2R)-2-{[(5R,6Z,8E,10E,12S,14Z)-5,12-dihydroxyicosa-6,8,10,14-tetraenoyl]oxy}-3-[(9Z)-hexadec-9-enoyloxy]propoxy](hydroxy)phosphoryl}oxy)-2-hydroxypropoxy]phosphonic acid

C42H74O15P2 (880.4502714)


PGP(16:1(9Z)/20:4(6Z,8E,10E,14Z)-2OH(5S,12R)) is an oxidized phosphoglycerophosphate (PGP). Oxidized phosphoglycerophosphates are glycerophospholipids in which a phosphoglycerol moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphoglycerophosphates belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphoglycerophosphates can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PGP(16:1(9Z)/20:4(6Z,8E,10E,14Z)-2OH(5S,12R)), in particular, consists of one chain of one 9Z-hexadecenoyl at the C-1 position and one chain of Leukotriene B4 at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PGPs can be synthesized via three different routes. In one route, the oxidized PGP is synthetized de novo following the same mechanisms as for PGPs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PGP backbone, mainely through the action of LOX (PMID: 33329396).

   

PGP(20:4(6Z,8E,10E,14Z)-2OH(5S,12R)/16:1(9Z))

[(2S)-3-({[(2R)-3-{[(5S,6Z,8E,10E,12R,14Z)-5,12-dihydroxyicosa-6,8,10,14-tetraenoyl]oxy}-2-[(9Z)-hexadec-9-enoyloxy]propoxy](hydroxy)phosphoryl}oxy)-2-hydroxypropoxy]phosphonic acid

C42H74O15P2 (880.4502714)


PGP(20:4(6Z,8E,10E,14Z)-2OH(5S,12R)/16:1(9Z)) is an oxidized phosphoglycerophosphate (PGP). Oxidized phosphoglycerophosphates are glycerophospholipids in which a phosphoglycerol moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphoglycerophosphates belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphoglycerophosphates can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PGP(20:4(6Z,8E,10E,14Z)-2OH(5S,12R)/16:1(9Z)), in particular, consists of one chain of one Leukotriene B4 at the C-1 position and one chain of 9Z-hexadecenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PGPs can be synthesized via three different routes. In one route, the oxidized PGP is synthetized de novo following the same mechanisms as for PGPs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PGP backbone, mainely through the action of LOX (PMID: 33329396).

   

PGP(16:1(9Z)/20:4(6E,8Z,11Z,13E)-2OH(5S,15S))

[(2S)-3-({[(2R)-2-{[(5S,6E,8Z,11Z,13E,15R)-5,15-dihydroxyicosa-6,8,11,13-tetraenoyl]oxy}-3-[(9Z)-hexadec-9-enoyloxy]propoxy](hydroxy)phosphoryl}oxy)-2-hydroxypropoxy]phosphonic acid

C42H74O15P2 (880.4502714)


PGP(16:1(9Z)/20:4(6E,8Z,11Z,13E)-2OH(5S,15S)) is an oxidized phosphoglycerophosphate (PGP). Oxidized phosphoglycerophosphates are glycerophospholipids in which a phosphoglycerol moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphoglycerophosphates belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphoglycerophosphates can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PGP(16:1(9Z)/20:4(6E,8Z,11Z,13E)-2OH(5S,15S)), in particular, consists of one chain of one 9Z-hexadecenoyl at the C-1 position and one chain of 5(S),15(S)-Dihydroxyeicosatetraenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PGPs can be synthesized via three different routes. In one route, the oxidized PGP is synthetized de novo following the same mechanisms as for PGPs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PGP backbone, mainely through the action of LOX (PMID: 33329396).

   

PGP(20:4(6E,8Z,11Z,13E)-2OH(5S,15S)/16:1(9Z))

[(2S)-3-({[(2R)-3-{[(5R,6E,8Z,11Z,13E,15S)-5,15-dihydroxyicosa-6,8,11,13-tetraenoyl]oxy}-2-[(9Z)-hexadec-9-enoyloxy]propoxy](hydroxy)phosphoryl}oxy)-2-hydroxypropoxy]phosphonic acid

C42H74O15P2 (880.4502714)


PGP(20:4(6E,8Z,11Z,13E)-2OH(5S,15S)/16:1(9Z)) is an oxidized phosphoglycerophosphate (PGP). Oxidized phosphoglycerophosphates are glycerophospholipids in which a phosphoglycerol moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphoglycerophosphates belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphoglycerophosphates can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PGP(20:4(6E,8Z,11Z,13E)-2OH(5S,15S)/16:1(9Z)), in particular, consists of one chain of one 5(S),15(S)-Dihydroxyeicosatetraenoyl at the C-1 position and one chain of 9Z-hexadecenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PGPs can be synthesized via three different routes. In one route, the oxidized PGP is synthetized de novo following the same mechanisms as for PGPs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PGP backbone, mainely through the action of LOX (PMID: 33329396).

   

PGP(16:1(9Z)/20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R))

[(2S)-3-({[(2R)-2-{[(5R,6R,8Z,11Z,14Z,17Z)-5,6-dihydroxyicosa-8,11,14,17-tetraenoyl]oxy}-3-[(9Z)-hexadec-9-enoyloxy]propoxy](hydroxy)phosphoryl}oxy)-2-hydroxypropoxy]phosphonic acid

C42H74O15P2 (880.4502714)


PGP(16:1(9Z)/20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R)) is an oxidized phosphoglycerophosphate (PGP). Oxidized phosphoglycerophosphates are glycerophospholipids in which a phosphoglycerol moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphoglycerophosphates belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphoglycerophosphates can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PGP(16:1(9Z)/20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R)), in particular, consists of one chain of one 9Z-hexadecenoyl at the C-1 position and one chain of 5,6-Dihydroxyeicosatetraenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PGPs can be synthesized via three different routes. In one route, the oxidized PGP is synthetized de novo following the same mechanisms as for PGPs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PGP backbone, mainely through the action of LOX (PMID: 33329396).

   

PGP(20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R)/16:1(9Z))

[(2S)-3-({[(2R)-3-{[(5S,6S,8Z,11Z,14Z,17Z)-5,6-dihydroxyicosa-8,11,14,17-tetraenoyl]oxy}-2-[(9Z)-hexadec-9-enoyloxy]propoxy](hydroxy)phosphoryl}oxy)-2-hydroxypropoxy]phosphonic acid

C42H74O15P2 (880.4502714)


PGP(20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R)/16:1(9Z)) is an oxidized phosphoglycerophosphate (PGP). Oxidized phosphoglycerophosphates are glycerophospholipids in which a phosphoglycerol moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphoglycerophosphates belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphoglycerophosphates can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PGP(20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R)/16:1(9Z)), in particular, consists of one chain of one 5,6-Dihydroxyeicosatetraenoyl at the C-1 position and one chain of 9Z-hexadecenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PGPs can be synthesized via three different routes. In one route, the oxidized PGP is synthetized de novo following the same mechanisms as for PGPs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PGP backbone, mainely through the action of LOX (PMID: 33329396).

   

PGP(i-16:0/PGJ2)

[(2S)-2-hydroxy-3-({hydroxy[(2R)-2-{[(5Z)-7-[(1S,5R)-5-[(1E,3S)-3-hydroxyoct-1-en-1-yl]-4-oxocyclopent-2-en-1-yl]hept-5-enoyl]oxy}-3-[(14-methylpentadecanoyl)oxy]propoxy]phosphoryl}oxy)propoxy]phosphonic acid

C42H74O15P2 (880.4502714)


PGP(i-16:0/PGJ2) is an oxidized phosphoglycerophosphate (PGP). Oxidized phosphoglycerophosphates are glycerophospholipids in which a phosphoglycerol moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphoglycerophosphates belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphoglycerophosphates can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PGP(i-16:0/PGJ2), in particular, consists of one chain of one 14-methylpentadecanoyl at the C-1 position and one chain of Prostaglandin J2 at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PGPs can be synthesized via three different routes. In one route, the oxidized PGP is synthetized de novo following the same mechanisms as for PGPs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PGP backbone, mainely through the action of LOX (PMID: 33329396).

   

PGP(PGJ2/i-16:0)

[(2S)-2-hydroxy-3-({hydroxy[(2R)-3-{[(5Z)-7-[(1S,5R)-5-[(1E,3S)-3-hydroxyoct-1-en-1-yl]-4-oxocyclopent-2-en-1-yl]hept-5-enoyl]oxy}-2-[(14-methylpentadecanoyl)oxy]propoxy]phosphoryl}oxy)propoxy]phosphonic acid

C42H74O15P2 (880.4502714)


PGP(PGJ2/i-16:0) is an oxidized phosphoglycerophosphate (PGP). Oxidized phosphoglycerophosphates are glycerophospholipids in which a phosphoglycerol moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphoglycerophosphates belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphoglycerophosphates can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PGP(PGJ2/i-16:0), in particular, consists of one chain of one Prostaglandin J2 at the C-1 position and one chain of 14-methylpentadecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PGPs can be synthesized via three different routes. In one route, the oxidized PGP is synthetized de novo following the same mechanisms as for PGPs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PGP backbone, mainely through the action of LOX (PMID: 33329396).

   
   

22-Acetoxyglycyrrhizin

(2S,3S,4S,5R,6R)-6-(((3S,4AR,6AR,6BS,8AR,9R,11R,12AS,14AR,14BS)-9-(ACETYLOXY)-11-CARBOXY-4,4,6A,6B,8A,11,14B-HEPTAMETHYL-14-OXO-1,2,3,4,4A,5,6,6A,6B,7,8,8A,9,10,11,12,12A,14,14A,14B-ICOSAHYDROPICEN-3-YL)OXY)-5-(((2R,3R,4S,5S,6S)-6-CARBOXY-3,4,5-TRIHYDROXYOXAN-2-YL)OXY)-3,4-DIHYDROXYOXANE-2-CARBOXYLIC ACID

C44H64O18 (880.4092444)


22-Acetoxyglycyrrhizin is a natural product found in Glycyrrhiza glabra and Glycyrrhiza inflata with data available. See also: Glycyrrhiza uralensis Root (part of).

   

4-tert-Butylcalix[4]arene tetraacetic acid

4-tert-Butylcalix[4]arene tetraacetic acid

C52H64O12 (880.4397544)


   
   

1-O-<2,4-di-O-acetyl-alpha-L-rhamnopyranosyl-(1--->2)-alpha-L-arabinopyranosyl>-epitrillogenin-24-O-acetate|1-O-[2,4-di-O-acetyl-alpha-L-rhamnopyranosyl-(1--->2)-alpha-L-arabinopyranosyl]-epitrillogenin-24-O-acetate

1-O-<2,4-di-O-acetyl-alpha-L-rhamnopyranosyl-(1--->2)-alpha-L-arabinopyranosyl>-epitrillogenin-24-O-acetate|1-O-[2,4-di-O-acetyl-alpha-L-rhamnopyranosyl-(1--->2)-alpha-L-arabinopyranosyl]-epitrillogenin-24-O-acetate

C43H60O19 (880.3728610000001)


   
   
   

spirocaracolitone F

spirocaracolitone F

C47H60O16 (880.388116)


   

1-O-<2,3,4-tri-O-acetyl-alpha-L-rhamnopyranosyl-(1--->2)-alpha-L-arabinopyranosyl>-epitrillogenin|1-O-[2,3,4-tri-O-acetyl-alpha-L-rhamnopyranosyl-(1--->2)-alpha-L-arabinopyranosyl]-epitrillogenin

1-O-<2,3,4-tri-O-acetyl-alpha-L-rhamnopyranosyl-(1--->2)-alpha-L-arabinopyranosyl>-epitrillogenin|1-O-[2,3,4-tri-O-acetyl-alpha-L-rhamnopyranosyl-(1--->2)-alpha-L-arabinopyranosyl]-epitrillogenin

C43H60O19 (880.3728610000001)


   

C44H64O18_Olean-12-en-29-oic acid, 22-(acetyloxy)-3-[(2-O-hexopyranuronosylhexopyranuronosyl)oxy]-11-oxo

NCGC00385549-01_C44H64O18_Olean-12-en-29-oic acid, 22-(acetyloxy)-3-[(2-O-hexopyranuronosylhexopyranuronosyl)oxy]-11-oxo-

C44H64O18 (880.4092444)


   
   
   

(1R-(1alpha,2alpha,3beta,9beta,13alpha,17beta,18alpha,19beta))-2,13,18-tris(carboxymethyl)-4,5,6,7,8,11,12,22-octadehydro-4,5,6,9,10,11,21,22-octahydro-3,5,8,9,13,15,18,19-octamethyl-3,7,12,17-Corrintetrapropanoic acid

(1R-(1alpha,2alpha,3beta,9beta,13alpha,17beta,18alpha,19beta))-2,13,18-tris(carboxymethyl)-4,5,6,7,8,11,12,22-octadehydro-4,5,6,9,10,11,21,22-octahydro-3,5,8,9,13,15,18,19-octamethyl-3,7,12,17-Corrintetrapropanoic acid

C45H60N4O14 (880.410582)


   

Nicotabaflavonoidglycoside

Nicotabaflavonoidglycoside

C47H60O16 (880.388116)


   

3-[(1R,2S,3S,5Z,7S,8S,13S,17R,18R,19R)-3,13,17-tris(2-carboxyethyl)-2,7,18-tris(carboxymethyl)-1,2,5,7,12,12,15,17-octamethyl-3,8,13,18,19,22-hexahydrocorrin-8-yl]propanoic acid

3-[(1R,2S,3S,5Z,7S,8S,13S,17R,18R,19R)-3,13,17-tris(2-carboxyethyl)-2,7,18-tris(carboxymethyl)-1,2,5,7,12,12,15,17-octamethyl-3,8,13,18,19,22-hexahydrocorrin-8-yl]propanoic acid

C45H60N4O14 (880.410582)


   

3-[(1R,2S,3S,7S,11S,17R,18R,19R)-8,13,17-tris(2-carboxyethyl)-2,7,18-tris(carboxymethyl)-1,2,5,7,11,12,15,17-octamethyl-3,10,15,18,19,22-hexahydrocorrin-3-yl]propanoic acid

3-[(1R,2S,3S,7S,11S,17R,18R,19R)-8,13,17-tris(2-carboxyethyl)-2,7,18-tris(carboxymethyl)-1,2,5,7,11,12,15,17-octamethyl-3,10,15,18,19,22-hexahydrocorrin-3-yl]propanoic acid

C45H60N4O14 (880.410582)


   
   
   
   
   

PGP(16:1(9Z)/20:4(6Z,8E,10E,14Z)-2OH(5S,12R))

PGP(16:1(9Z)/20:4(6Z,8E,10E,14Z)-2OH(5S,12R))

C42H74O15P2 (880.4502714)


   

PGP(20:4(6Z,8E,10E,14Z)-2OH(5S,12R)/16:1(9Z))

PGP(20:4(6Z,8E,10E,14Z)-2OH(5S,12R)/16:1(9Z))

C42H74O15P2 (880.4502714)


   

PGP(16:1(9Z)/20:4(6E,8Z,11Z,13E)-2OH(5S,15S))

PGP(16:1(9Z)/20:4(6E,8Z,11Z,13E)-2OH(5S,15S))

C42H74O15P2 (880.4502714)


   

PGP(20:4(6E,8Z,11Z,13E)-2OH(5S,15S)/16:1(9Z))

PGP(20:4(6E,8Z,11Z,13E)-2OH(5S,15S)/16:1(9Z))

C42H74O15P2 (880.4502714)


   

PGP(16:1(9Z)/20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R))

PGP(16:1(9Z)/20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R))

C42H74O15P2 (880.4502714)


   

PGP(20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R)/16:1(9Z))

PGP(20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R)/16:1(9Z))

C42H74O15P2 (880.4502714)


   

(1R,2R,3R,7S,12S,13S,17S,18S,19R)-3,5,8,8,13,15,18,19-Octamethyl-2,13,18-tris(carboxymethyl)corrin-3,7,12,17-tetrapropanoic acid

(1R,2R,3R,7S,12S,13S,17S,18S,19R)-3,5,8,8,13,15,18,19-Octamethyl-2,13,18-tris(carboxymethyl)corrin-3,7,12,17-tetrapropanoic acid

C45H60N4O14 (880.410582)


   

2-[[(3S,6S,9S,12S,15R)-3-benzyl-12-[(2S)-butan-2-yl]-9-[2-(4-hydroxyphenyl)ethyl]-6,7-dimethyl-2,5,8,11,14-pentaoxo-1,4,7,10,13-pentazacyclononadec-15-yl]carbamoylamino]-3-(1H-indol-3-yl)propanoic acid

2-[[(3S,6S,9S,12S,15R)-3-benzyl-12-[(2S)-butan-2-yl]-9-[2-(4-hydroxyphenyl)ethyl]-6,7-dimethyl-2,5,8,11,14-pentaoxo-1,4,7,10,13-pentazacyclononadec-15-yl]carbamoylamino]-3-(1H-indol-3-yl)propanoic acid

C47H60N8O9 (880.448303)


   
   
   
   
   
   

Neurokinin A(4-10) (TFA)

Neurokinin A(4-10) (TFA)

C36H55F3N8O12S (880.3612066)


Neurokinin A (4-10) TFA is a tachykinin NK2 receptor agonist[1].

   

(2s,3r,4r,5s,6s)-4,5-bis(acetyloxy)-2-{[(2s,3r,4s,5s)-4,5-dihydroxy-2-[(1'r,2s,3s,4s,4'r,5s,7'r,8'r,12's,13'r,14'r,16'r)-3,4,16'-trihydroxy-7'-(hydroxymethyl)-5,13'-dimethyl-5'-oxaspiro[oxane-2,6'-pentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosane]-2'(9'),18'-dien-3'-oneoxy]oxan-3-yl]oxy}-6-methyloxan-3-yl acetate

(2s,3r,4r,5s,6s)-4,5-bis(acetyloxy)-2-{[(2s,3r,4s,5s)-4,5-dihydroxy-2-[(1'r,2s,3s,4s,4'r,5s,7'r,8'r,12's,13'r,14'r,16'r)-3,4,16'-trihydroxy-7'-(hydroxymethyl)-5,13'-dimethyl-5'-oxaspiro[oxane-2,6'-pentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosane]-2'(9'),18'-dien-3'-oneoxy]oxan-3-yl]oxy}-6-methyloxan-3-yl acetate

C43H60O19 (880.3728610000001)


   

(1s,1's,2r,3s,3as,4r,5s,5's,6'r,7r,7's,7as,9'r)-3,5',7'-tris(acetyloxy)-3a-[(acetyloxy)methyl]-5-[(2r)-1-methoxy-1-oxopropan-2-yl]-4-(2-methoxy-2-oxoethyl)-2,3',5,6',9'-pentamethyl-10'-oxo-2,3,4,6,7,7a-hexahydro-11'-oxaspiro[indene-1,2'-tricyclo[7.2.1.0¹,⁶]dodecan]-3'-en-7-yl benzoate

(1s,1's,2r,3s,3as,4r,5s,5's,6'r,7r,7's,7as,9'r)-3,5',7'-tris(acetyloxy)-3a-[(acetyloxy)methyl]-5-[(2r)-1-methoxy-1-oxopropan-2-yl]-4-(2-methoxy-2-oxoethyl)-2,3',5,6',9'-pentamethyl-10'-oxo-2,3,4,6,7,7a-hexahydro-11'-oxaspiro[indene-1,2'-tricyclo[7.2.1.0¹,⁶]dodecan]-3'-en-7-yl benzoate

C47H60O16 (880.388116)


   

(1'r,2s,3s,4s,4'r,5s,7'r,8'r,12's,13'r,14'r,16'r)-14'-{[(2s,3r,4s,5s)-3-{[(2s,3r,4r,5r,6s)-3,5-bis(acetyloxy)-4-hydroxy-6-methyloxan-2-yl]oxy}-4,5-dihydroxyoxan-2-yl]oxy}-3,16'-dihydroxy-7'-(hydroxymethyl)-5,13'-dimethyl-3'-oxo-5'-oxaspiro[oxane-2,6'-pentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosane]-2'(9'),18'-dien-4-yl acetate

(1'r,2s,3s,4s,4'r,5s,7'r,8'r,12's,13'r,14'r,16'r)-14'-{[(2s,3r,4s,5s)-3-{[(2s,3r,4r,5r,6s)-3,5-bis(acetyloxy)-4-hydroxy-6-methyloxan-2-yl]oxy}-4,5-dihydroxyoxan-2-yl]oxy}-3,16'-dihydroxy-7'-(hydroxymethyl)-5,13'-dimethyl-3'-oxo-5'-oxaspiro[oxane-2,6'-pentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosane]-2'(9'),18'-dien-4-yl acetate

C43H60O19 (880.3728610000001)


   

n-{5-benzyl-6,13,16,21-tetrahydroxy-15-[2-(4-hydroxyphenyl)ethyl]-4,11-dimethyl-3,9,22-trioxo-2,8-bis(sec-butyl)-10-oxa-1,4,7,14,17-pentaazabicyclo[16.3.1]docosa-6,13,16-trien-12-yl}-3-hydroxy-2-methoxypropanimidic acid

n-{5-benzyl-6,13,16,21-tetrahydroxy-15-[2-(4-hydroxyphenyl)ethyl]-4,11-dimethyl-3,9,22-trioxo-2,8-bis(sec-butyl)-10-oxa-1,4,7,14,17-pentaazabicyclo[16.3.1]docosa-6,13,16-trien-12-yl}-3-hydroxy-2-methoxypropanimidic acid

C45H64N6O12 (880.4581984)


   

(2s,3s,4s,5r,6s)-6-{[(3s,4ar,6ar,6bs,8ar,9r,11r,12as,14ar,14bs)-9-(acetyloxy)-11-carboxy-4,4,6a,6b,8a,11,14b-heptamethyl-14-oxo-2,3,4a,5,6,7,8,9,10,12,12a,14a-dodecahydro-1h-picen-3-yl]oxy}-5-{[(2r,3r,4s,5s,6s)-6-carboxy-3,4,5-trihydroxyoxan-2-yl]oxy}-3,4-dihydroxyoxane-2-carboxylic acid

(2s,3s,4s,5r,6s)-6-{[(3s,4ar,6ar,6bs,8ar,9r,11r,12as,14ar,14bs)-9-(acetyloxy)-11-carboxy-4,4,6a,6b,8a,11,14b-heptamethyl-14-oxo-2,3,4a,5,6,7,8,9,10,12,12a,14a-dodecahydro-1h-picen-3-yl]oxy}-5-{[(2r,3r,4s,5s,6s)-6-carboxy-3,4,5-trihydroxyoxan-2-yl]oxy}-3,4-dihydroxyoxane-2-carboxylic acid

C44H64O18 (880.4092444)


   

3,5',7'-tris(acetyloxy)-3a-[(acetyloxy)methyl]-5-(1-methoxy-1-oxopropan-2-yl)-4-(2-methoxy-2-oxoethyl)-2,3',5,6',9'-pentamethyl-10'-oxo-2,3,4,6,7,7a-hexahydro-11'-oxaspiro[indene-1,2'-tricyclo[7.2.1.0¹,⁶]dodecan]-3'-en-7-yl benzoate

3,5',7'-tris(acetyloxy)-3a-[(acetyloxy)methyl]-5-(1-methoxy-1-oxopropan-2-yl)-4-(2-methoxy-2-oxoethyl)-2,3',5,6',9'-pentamethyl-10'-oxo-2,3,4,6,7,7a-hexahydro-11'-oxaspiro[indene-1,2'-tricyclo[7.2.1.0¹,⁶]dodecan]-3'-en-7-yl benzoate

C47H60O16 (880.388116)


   

4,5-bis(acetyloxy)-2-({4,5-dihydroxy-2-[3,4,16'-trihydroxy-7'-(hydroxymethyl)-5,13'-dimethyl-5'-oxaspiro[oxane-2,6'-pentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosane]-2'(9'),18'-dien-3'-oneoxy]oxan-3-yl}oxy)-6-methyloxan-3-yl acetate

4,5-bis(acetyloxy)-2-({4,5-dihydroxy-2-[3,4,16'-trihydroxy-7'-(hydroxymethyl)-5,13'-dimethyl-5'-oxaspiro[oxane-2,6'-pentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosane]-2'(9'),18'-dien-3'-oneoxy]oxan-3-yl}oxy)-6-methyloxan-3-yl acetate

C43H60O19 (880.3728610000001)


   

(1s,3s,5z,7r,8e,11s,12s,13e,15s,17r,21r,23r,25s)-12-(butanoyloxy)-1,11,21-trihydroxy-17-[(1r)-1-hydroxyethyl]-5,13-bis(2-methoxy-2-oxoethylidene)-10,10,26,26-tetramethyl-19-oxo-18,27,28,29-tetraoxatetracyclo[21.3.1.1³,⁷.1¹¹,¹⁵]nonacos-8-en-25-yl butanoate

(1s,3s,5z,7r,8e,11s,12s,13e,15s,17r,21r,23r,25s)-12-(butanoyloxy)-1,11,21-trihydroxy-17-[(1r)-1-hydroxyethyl]-5,13-bis(2-methoxy-2-oxoethylidene)-10,10,26,26-tetramethyl-19-oxo-18,27,28,29-tetraoxatetracyclo[21.3.1.1³,⁷.1¹¹,¹⁵]nonacos-8-en-25-yl butanoate

C45H68O17 (880.4456278)


   

2-({[(3s,6s,9s,12s,15r)-3-benzyl-2,5,11,14-tetrahydroxy-9-[2-(4-hydroxyphenyl)ethyl]-6,7-dimethyl-8-oxo-12-(sec-butyl)-1,4,7,10,13-pentaazacyclononadeca-1,4,10,13-tetraen-15-yl]-c-hydroxycarbonimidoyl}amino)-3-(1h-indol-3-yl)propanoic acid

2-({[(3s,6s,9s,12s,15r)-3-benzyl-2,5,11,14-tetrahydroxy-9-[2-(4-hydroxyphenyl)ethyl]-6,7-dimethyl-8-oxo-12-(sec-butyl)-1,4,7,10,13-pentaazacyclononadeca-1,4,10,13-tetraen-15-yl]-c-hydroxycarbonimidoyl}amino)-3-(1h-indol-3-yl)propanoic acid

C47H60N8O9 (880.448303)


   

9-(2,3-dihydroxy-2-methylpropyl)-1,4,7,10,13,16,22,23-octahydroxy-15-(1-hydroxyethyl)-18-(hydroxymethyl)-12-isopropyl-6-[(2-methanesulfinyl-1h-indol-3-yl)methyl]-3-methyl-3h,6h,9h,12h,15h,18h,21h,22h,23h,23ah-pyrrolo[1,2-a]1,4,7,10,13,16,19-heptaazacyclohenicosan-19-one

9-(2,3-dihydroxy-2-methylpropyl)-1,4,7,10,13,16,22,23-octahydroxy-15-(1-hydroxyethyl)-18-(hydroxymethyl)-12-isopropyl-6-[(2-methanesulfinyl-1h-indol-3-yl)methyl]-3-methyl-3h,6h,9h,12h,15h,18h,21h,22h,23h,23ah-pyrrolo[1,2-a]1,4,7,10,13,16,19-heptaazacyclohenicosan-19-one

C38H56N8O14S (880.3636516)


   

2-[({3-benzyl-2,5,11,14-tetrahydroxy-9-[2-(4-hydroxyphenyl)ethyl]-6,7-dimethyl-8-oxo-12-(sec-butyl)-1,4,7,10,13-pentaazacyclononadeca-1,4,10,13-tetraen-15-yl}-c-hydroxycarbonimidoyl)amino]-3-(1h-indol-3-yl)propanoic acid

2-[({3-benzyl-2,5,11,14-tetrahydroxy-9-[2-(4-hydroxyphenyl)ethyl]-6,7-dimethyl-8-oxo-12-(sec-butyl)-1,4,7,10,13-pentaazacyclononadeca-1,4,10,13-tetraen-15-yl}-c-hydroxycarbonimidoyl)amino]-3-(1h-indol-3-yl)propanoic acid

C47H60N8O9 (880.448303)


   

(1s,3s,5z,7r,8z,11s,12s,13e,15s,17r,21r,23r,25s)-12-(butanoyloxy)-1,11,21-trihydroxy-17-[(1r)-1-hydroxyethyl]-5,13-bis(2-methoxy-2-oxoethylidene)-10,10,26,26-tetramethyl-19-oxo-18,27,28,29-tetraoxatetracyclo[21.3.1.1³,⁷.1¹¹,¹⁵]nonacos-8-en-25-yl butanoate

(1s,3s,5z,7r,8z,11s,12s,13e,15s,17r,21r,23r,25s)-12-(butanoyloxy)-1,11,21-trihydroxy-17-[(1r)-1-hydroxyethyl]-5,13-bis(2-methoxy-2-oxoethylidene)-10,10,26,26-tetramethyl-19-oxo-18,27,28,29-tetraoxatetracyclo[21.3.1.1³,⁷.1¹¹,¹⁵]nonacos-8-en-25-yl butanoate

C45H68O17 (880.4456278)


   

(2r)-2-{[(2s)-6-amino-2-{[(4r)-4-{[(2s)-2-[(2-{[(2r,3s,4r,5r)-3-{[(2s,3r,4r,5s,6r)-4,5-dihydroxy-3-[(1-hydroxyethylidene)amino]-6-(hydroxymethyl)oxan-2-yl]oxy}-5-(ethylamino)-6-hydroxy-2-(hydroxymethyl)oxan-4-yl]oxy}-1-hydroxypropylidene)amino]-1-hydroxypropylidene]amino}-1-hydroxy-4-(c-hydroxycarbonimidoyl)butylidene]amino}-1-hydroxyhexylidene]amino}propanoic acid

(2r)-2-{[(2s)-6-amino-2-{[(4r)-4-{[(2s)-2-[(2-{[(2r,3s,4r,5r)-3-{[(2s,3r,4r,5s,6r)-4,5-dihydroxy-3-[(1-hydroxyethylidene)amino]-6-(hydroxymethyl)oxan-2-yl]oxy}-5-(ethylamino)-6-hydroxy-2-(hydroxymethyl)oxan-4-yl]oxy}-1-hydroxypropylidene)amino]-1-hydroxypropylidene]amino}-1-hydroxy-4-(c-hydroxycarbonimidoyl)butylidene]amino}-1-hydroxyhexylidene]amino}propanoic acid

C36H64N8O17 (880.4389214)


   

14'-[(3-{[3,5-bis(acetyloxy)-4-hydroxy-6-methyloxan-2-yl]oxy}-4,5-dihydroxyoxan-2-yl)oxy]-3,16'-dihydroxy-7'-(hydroxymethyl)-5,13'-dimethyl-3'-oxo-5'-oxaspiro[oxane-2,6'-pentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosane]-2'(9'),18'-dien-4-yl acetate

14'-[(3-{[3,5-bis(acetyloxy)-4-hydroxy-6-methyloxan-2-yl]oxy}-4,5-dihydroxyoxan-2-yl)oxy]-3,16'-dihydroxy-7'-(hydroxymethyl)-5,13'-dimethyl-3'-oxo-5'-oxaspiro[oxane-2,6'-pentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosane]-2'(9'),18'-dien-4-yl acetate

C43H60O19 (880.3728610000001)


   

3-[(1r,3r,4r,8s,13s,14s,18s,19s)-4,13,18-tris(2-carboxyethyl)-3,14,19-tris(carboxymethyl)-1,4,6,9,9,14,16,19-octamethyl-20,21,22,23-tetraazapentacyclo[15.2.1.1²,⁵.1⁷,¹⁰.1¹²,¹⁵]tricosa-5(23),6,10(22),11,15(21),16-hexaen-8-yl]propanoic acid

3-[(1r,3r,4r,8s,13s,14s,18s,19s)-4,13,18-tris(2-carboxyethyl)-3,14,19-tris(carboxymethyl)-1,4,6,9,9,14,16,19-octamethyl-20,21,22,23-tetraazapentacyclo[15.2.1.1²,⁵.1⁷,¹⁰.1¹²,¹⁵]tricosa-5(23),6,10(22),11,15(21),16-hexaen-8-yl]propanoic acid

C45H60N4O14 (880.410582)


   

(2r)-n-[(2s,5s,8s,11r,12s,15s,18s,21r)-5-benzyl-2,8-bis[(2s)-butan-2-yl]-6,13,16,21-tetrahydroxy-15-[2-(4-hydroxyphenyl)ethyl]-4,11-dimethyl-3,9,22-trioxo-10-oxa-1,4,7,14,17-pentaazabicyclo[16.3.1]docosa-6,13,16-trien-12-yl]-3-hydroxy-2-methoxypropanimidic acid

(2r)-n-[(2s,5s,8s,11r,12s,15s,18s,21r)-5-benzyl-2,8-bis[(2s)-butan-2-yl]-6,13,16,21-tetrahydroxy-15-[2-(4-hydroxyphenyl)ethyl]-4,11-dimethyl-3,9,22-trioxo-10-oxa-1,4,7,14,17-pentaazabicyclo[16.3.1]docosa-6,13,16-trien-12-yl]-3-hydroxy-2-methoxypropanimidic acid

C45H64N6O12 (880.4581984)


   

3-[(1r,2r,3r,4r,8s,13s,14s,18s,19s)-4,13,18-tris(2-carboxyethyl)-3,14,19-tris(carboxymethyl)-1,4,6,9,9,14,16,19-octamethyl-20,21,22,23-tetraazapentacyclo[15.2.1.1²,⁵.1⁷,¹⁰.1¹²,¹⁵]tricosa-5(23),6,10(22),11,15(21),16-hexaen-8-yl]propanoic acid

3-[(1r,2r,3r,4r,8s,13s,14s,18s,19s)-4,13,18-tris(2-carboxyethyl)-3,14,19-tris(carboxymethyl)-1,4,6,9,9,14,16,19-octamethyl-20,21,22,23-tetraazapentacyclo[15.2.1.1²,⁵.1⁷,¹⁰.1¹²,¹⁵]tricosa-5(23),6,10(22),11,15(21),16-hexaen-8-yl]propanoic acid

C45H60N4O14 (880.410582)


   

(1s,1'r,2r,3s,3as,4r,5s,5's,6'r,7r,7's,7as,9'r)-3,5',7'-tris(acetyloxy)-3a-[(acetyloxy)methyl]-5-[(2r)-1-methoxy-1-oxopropan-2-yl]-4-(2-methoxy-2-oxoethyl)-2,3',5,6',9'-pentamethyl-10'-oxo-2,3,4,6,7,7a-hexahydro-11'-oxaspiro[indene-1,2'-tricyclo[7.2.1.0¹,⁶]dodecan]-3'-en-7-yl benzoate

(1s,1'r,2r,3s,3as,4r,5s,5's,6'r,7r,7's,7as,9'r)-3,5',7'-tris(acetyloxy)-3a-[(acetyloxy)methyl]-5-[(2r)-1-methoxy-1-oxopropan-2-yl]-4-(2-methoxy-2-oxoethyl)-2,3',5,6',9'-pentamethyl-10'-oxo-2,3,4,6,7,7a-hexahydro-11'-oxaspiro[indene-1,2'-tricyclo[7.2.1.0¹,⁶]dodecan]-3'-en-7-yl benzoate

C47H60O16 (880.388116)